Pfizer Inc. (PFE)

37.22
0.06 0.16
NYSE : Health Technology
Prev Close 37.28
Open 37.39
Day Low/High 36.96 / 37.44
52 Wk Low/High 33.97 / 46.47
Volume 17.16M
Avg Volume 19.41M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 202.27B
EPS 1.90
P/E Ratio 12.60
Div & Yield 1.44 (3.88%)

Latest News

Slop and Chop Continues

Breadth leaked, new lows grew and the McClellan Summation Index rolled over a week ago and shows no sign or recapturing the uptrend.

Mylan And Pfizer Announce Viatris As The New Company Name In The Planned Mylan-Upjohn Combination

Mylan And Pfizer Announce Viatris As The New Company Name In The Planned Mylan-Upjohn Combination

HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Mylan N.

Pfizer Announces Results Of Phase 3 Study For XELJANZ® (tofacitinib) In Juvenile Idiopathic Arthritis Ahead Of Presentation At 2019 American College Of Rheumatology/Association Of Rheumatology Professionals Annual Meeting

Pfizer Announces Results Of Phase 3 Study For XELJANZ® (tofacitinib) In Juvenile Idiopathic Arthritis Ahead Of Presentation At 2019 American College Of Rheumatology/Association Of Rheumatology Professionals Annual Meeting

Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic arthritis (JIA) will be presented for the first time during a...

EMD Serono And Pfizer Provide Update On Phase III JAVELIN Gastric 100 Trial

EMD Serono And Pfizer Provide Update On Phase III JAVELIN Gastric 100 Trial

Not intended for UK-based media

Pfizer's Long-Term Outlook Is Murky, Says UBS on Lowering Price Target

Pfizer's Long-Term Outlook Is Murky, Says UBS on Lowering Price Target

UBS lowers its price target on Pfizer to $37 a share and maintains its neutral rating on the stock.

Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast

Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast

The company generates increased sales from its existing suite of generic drugs as well as some new product launches.

Mylan Doles Out the Right Prescription for Investors

Mylan Doles Out the Right Prescription for Investors

Strong demand for its lineup of generic drugs and more to come from additional upcoming launches as it moves toward closing its deal with Pfizer's PFE Upjohn business all helped boost third-quarter sales and earnings for Mylan.

Forget About the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/30/19)

Forget About the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/30/19)

Jim Cramer says not having enough time, and having too much government regulation, have more impact on the future revenue streams of companies than does the Federal Reserve.

Pfizer's Latest Move Points to 14% Upside Ahead

Pfizer's Latest Move Points to 14% Upside Ahead

Pfizer's earnings pop could lead the way to a change in trend.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #19 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #285 spot.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Fiat Chrysler, Fed, Apple, AMD, GE - 5 Things You Must Know Wednesday

Fiat Chrysler, Fed, Apple, AMD, GE - 5 Things You Must Know Wednesday

U.S. stock futures are mixed as Wall Street awaits an expected rate cut - the third this year - from the Federal Reserve on Wednesday and earnings from Apple; Facebook, General Electric, Starbucks and Twilio also report earnings Wednesday; Fiat Chrysler and Peugeot owner PSA confirm they are in merger talks.

Dow Ends Lower; S&P 500 Slips After Intraday Record on Strong Pharma Earnings

Dow Ends Lower; S&P 500 Slips After Intraday Record on Strong Pharma Earnings

Stocks finish lower Tuesday, even though the S&P 500 sets an intraday record high.

Pfizer Tops Q3 Earnings Forecast, Boosts Full Year Profit Guidance: Shares Gain

Pfizer Tops Q3 Earnings Forecast, Boosts Full Year Profit Guidance: Shares Gain

Pfizer posted stronger-than-expected third quarter earnings Tuesday, and boosted its full-year profit guidance, sending shares higher in pre-market trading.

Dow Futures Slide, S&P 500 Eases From Record Highs Ahead of Fed Rate Meeting

Dow Futures Slide, S&P 500 Eases From Record Highs Ahead of Fed Rate Meeting

Wall Street futures eased from record highs Tuesday, while global stocks traded mixed amid renewed optimism on U.S.-China trade talks and the expectation of near-term rate support from the Federal Reserve.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Alphabet, Federal Reserve, BP, Pfizer and AMD - 5 Things You Must Know

Alphabet, Federal Reserve, BP, Pfizer and AMD - 5 Things You Must Know

U.S. stock futures are mixed Tuesday amid renewed optimism on U.S.-China trade talks and the expectation of near-term rate support from the Federal Reserve; the U.S. central bank begins a two-day meeting Tuesday and is expected Wednesday to announce it has cut rates for third third time in 2019; Alphabet falls after earnings miss analysts' expectations.

PFIZER REPORTS THIRD-QUARTER 2019 RESULTS

PFIZER REPORTS THIRD-QUARTER 2019 RESULTS

Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.

Value Over Growth? Don’t Bet on It

Several times we’ve seen value outperform growth over the years and it has rarely continued longer than a few months.

Rallying on a Downside Surprise?: Cramer's 'Mad Money' Recap (Thursday 10/17/19)

Rallying on a Downside Surprise?: Cramer's 'Mad Money' Recap (Thursday 10/17/19)

Jim Cramer explains the unexpected: quarterly results are 'not as bad as feared' -- NABAF. It's boosting stocks that, based on the headlines, should really just crumple.

Pfizer Presents Positive Phase 3 Data At The 28th Congress Of The European Academy Of Dermatology And Venereology For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer Presents Positive Phase 3 Data At The 28th Congress Of The European Academy Of Dermatology And Venereology For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD).

Akcea Stocks Soars on Pfizer Licensing Agreement

Akcea Stocks Soars on Pfizer Licensing Agreement

Akcea shares soar after the company announces a licensing agreement with Pfizer for its treatment for people with certain cardiovascular and metabolic diseases.

Dow Finishes Higher as Wall Street Bounces Back, Probability Climbs for Rate Cut

Dow Finishes Higher as Wall Street Bounces Back, Probability Climbs for Rate Cut

Stocks finish higher after falling earlier in the session following a weak reading on U.S. services sector activity.

Pfizer Presents Interim Analysis Results From Phase 3 BEACON CRC Trial Of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) And Cetuximab For The Treatment Of BRAFV600E-Mutant Metastatic Colorectal Cancer

Pfizer Presents Interim Analysis Results From Phase 3 BEACON CRC Trial Of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) And Cetuximab For The Treatment Of BRAFV600E-Mutant Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI ® (encorafenib), MEKTOVI ® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced...

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.

Pfizer Inc. Awards "Golden Tickets" To Neutrolis And Mediar Therapeutics

Pfizer Inc. Awards "Golden Tickets" To Neutrolis And Mediar Therapeutics

Pfizer Inc. and LabCentral announced that Pfizer has selected Neutrolis and Mediar Therapeutics are the winners of this year's Pfizer Golden Ticket Program.

TheStreet Quant Rating: B (Buy)